Decoy Receptor 3 Expression Is AssociatedWith Wild-Type EGFR Status, PoorDifferentiation of Tumor, and UnfavorablePatient Outcome: ClinicopathologicAnalyses of 461 Lung Adenocarcinomas

Objectives The role of decoy receptor 3 (DcR3) in lung cancer, particularlyadenocarcinoma, has not been well studied. In this study, weaim to investigate the expression profile and theclinicopathologic implications of DcR3 expression in lungadenocarcinoma. Methods Immunohistochemistry was used to examine DcR3 expression in461 lung adenocarcinomas. The differences in DcR3 expressionamong the various histopathologic patterns were analyzed. Therelationship between DcR3 expression and clinicopathologicparameters, including epidermal growth factor receptor (EGFR)mutation, was also investigated. Results DcR3 expression was more frequently expressed in solid,micropapillary, and acinar patterns (P < .0001) and in tumorswith wild-type EGFR status (P = .018). In addition, DcR3expression portends a less favorable disease-free survival instage I patients (P = .012). Conclusions The expression of DcR3 might be involved in the differentiationand progression of lung adenocarcinoma. Therefore, DcR3 maybe applied clinically for prediction of tumor progression in stageI lung adenocarcinoma.